Johnson & Johnson (NYSE:JNJ) Shares Sold by Town & Country Bank & Trust CO dba First Bankers Trust CO

Town & Country Bank & Trust CO dba First Bankers Trust CO lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,488 shares of the company’s stock after selling 210 shares during the quarter. Johnson & Johnson accounts for approximately 2.5% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s investment portfolio, making the stock its 7th largest position. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Johnson & Johnson were worth $5,772,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Alerus Financial NA increased its stake in shares of Johnson & Johnson by 1.7% in the third quarter. Alerus Financial NA now owns 4,299 shares of the company’s stock valued at $670,000 after buying an additional 71 shares during the period. Elevatus Welath Management increased its position in Johnson & Johnson by 29.1% during the 3rd quarter. Elevatus Welath Management now owns 1,802 shares of the company’s stock valued at $281,000 after purchasing an additional 406 shares during the period. Legacy Advisors LLC increased its position in Johnson & Johnson by 6.3% during the 3rd quarter. Legacy Advisors LLC now owns 72,571 shares of the company’s stock valued at $11,303,000 after purchasing an additional 4,279 shares during the period. Lakeshore Financial Planning Inc. acquired a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $460,000. Finally, KPP Advisory Services LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $1,828,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $146.16 on Monday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The business’s fifty day moving average is $148.14 and its 200 day moving average is $154.05. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The stock has a market cap of $351.76 billion, a P/E ratio of 9.11, a P/E/G ratio of 2.43 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period last year, the business earned $2.68 EPS. The business’s revenue was up 2.3% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.39%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on JNJ shares. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Thursday, June 20th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a report on Monday, June 17th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.